Si-b036
Phase 1
Si-b036 is one of 71 therapeutic programs targeting Solid Tumor. It is currently in Phase 1.
6
Indications
6
Total Trials
6
Active Trials
70
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lexiscan
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Si-b036
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 1
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Rilvegostomig
AstraZenecaPreclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2028
Phase 1Recruiting
Breast Cancer
NCT07753226
Phase 1Recruiting
Gastrointestinal Tumor
NCT07678970
Phase 1Not yet recruiting
Gynecological Tumors
NCT07778862
Phase 1Not yet recruiting
Urological Cancer
NCT07744243
Phase 1Not yet recruiting
Head and Neck Tumors
NCT07763639
Phase 1Recruiting
Solid Tumor
NCT07606612
Clinical
Trials by Indication[1]
Breast Cancer1 trial
Gastrointestinal Tumor1 trial
Gynecological Tumors1 trial
Urological Cancer1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Si-b036. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]